HIKMA Pharmaceuticals PLC — Share Issue/Capital Change 2015

Jan 15, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2457C

Hikma Pharmaceuticals Plc

15 January 2015

Block Listing of Shares

Hikma PharmaceuticalsPLC

LONDON, 15 January 2015 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ: HIK), announces that it has made a block listing application to the Financial Conduct Authority and the London Stock Exchange plc for a total of 500,000 ordinary shares of 10p each in the capital of the Company to be admitted to the Official List of the UK Listing Authority.  It is expected that admission will be granted on 16 January 2015. 

The shares, when issued, will be issued fully paid and rank pari passu in all respects with the existing issued ordinary shares of the Company.  The shares will be issued pursuant to the vesting of shares under the Hikma Pharmaceuticals PLC 2005 Long Term Incentive Plan and the 2009 Management Incentive Plan (the "Plans"). Participants in the Plans have or will become entitled to these shares following the vesting of the shares.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	+44 20 7399 2760

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BLRGMGMMGKFGKZM